4 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Terminated 1 |
Follow Lennox Gastaut Syndrome: new trials by email Literature Review of Lennox Gastaut Syndrome trials Research Report on Lennox Gastaut Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome CBD: GT4 Transdermal Delivery System - Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS) | Phase 1 / Phase 2 | Not yet recruiting | Alexander Rotenberg | 25 | 2025-01-01 | 2024-12-18 |
| BMB-101 in Absence Epilepsy and DEE BMB-101 - Absence Epilepsy, Jeavons Syndrome | Phase 2 | Recruiting | Bright Minds Biosciences Pty Ltd | 20 | 2024-12-05 | 2025-08-12 |
| Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy LP352, bexicaserin - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 2 | Completed | Longboard Pharmaceuticals | 41 | 2022-11-08 | 2025-12-03 |
| RNS System LGS Feasibility Study RNS System - Epilepsy, Lennox Gastaut Syndrome | Phase 2 | Active not recruiting | NeuroPace | 24 | 2022-10-04 | 2026-09-15 |
| Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies LP352, Placebo - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 1 / Phase 2 | Completed | Longboard Pharmaceuticals | 52 | 2022-03-03 | 2024-11-08 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies TAK-935, Placebo - Epilepsy, Dravet Syndrome | Phase 2 | Completed | Takeda | 141 | 2018-08-08 | 2026-09-14 |
| A Study of Soticlestat in Adults and Children With Rare Epilepsies Soticlestat - Epilepsy, Dravet Syndrome (DS) | Phase 2 | Terminated | Takeda | 156 | 2018-07-19 | 2026-09-04 |
| The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy 12-Lead ECG, Cannabidiol - Lennox-Gastaut Syndrome, Dravet Syndrome | Phase 1 / Phase 2 | Terminated | Gillette Children's Specialty Healthcare | 2 | 2017-02-16 | 2022-08-30 |
| Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy Fenfluramine - Epilepsy, Lennox Gastaut Syndrome | Phase 2 | Completed | KU Leuven | 13 | 2016-01-01 | 2026-10-20 |
Epilepsies, Myoclonic (7) · Epilepsy (6) · CDKL5 deficiency disorder (3) · Tuberous Sclerosis (3) · Seizures (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Epilepsy, Absence (1) · Hypoxia-Ischemia, Brain (1) · Malformations of Cortical Development (1) · Nervous System Diseases (1) · Spasms, Infantile (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Epileptic Syndromes (9) · Genetic Diseases, Inborn (9) · Brain Diseases (8) · Central Nervous System Diseases (8) · Nervous System Diseases (8) · Epilepsy, Generalized (7) · Congenital Abnormalities (3) · Epilepsy (3) · Hamartoma (3) · Heredodegenerative Disorders, Nervous System (3) · Malformations of Cortical Development, Group I (3) · Neoplasms (3) · Neoplasms, Multiple Primary (3) · Neoplastic Syndromes, Hereditary (3)
Cannabidiol (1) · Fenfluramine (1) · soticlestat (1)
Longboard Pharmaceuticals (2) · Takeda (2) · Alexander Rotenberg (1) · Bright Minds Biosciences Pty Ltd (1) · Gillette Children's Specialty Healthcare (1) · KU Leuven (1) · NeuroPace (1)
United States (7) · Australia (5) · Canada (2) · China (2) · Israel (2) · Poland (2) · Portugal (2) · Spain (2) · Belgium (1)
Dennis J Dlugos, MD (2) · Alexander Rotenberg, MD, PhD (1) · Beverly S Wical, MD (1) · Lieven G Lagae, MD, PhD (1) · Martha Morrell, MD (1) · Terence O'Brien, MD (1)
PMID 30146701, PMID 35841234, PMID 42663529
2018 (2), UH3NS109557 (1)